Be0290

Manufactured by BioXCell

The BE0290 is a laboratory centrifuge from BioXCell. It is designed to separate different components of a liquid sample based on their density and sedimentation rate. The centrifuge can reach a maximum speed of 15,000 revolutions per minute and has a maximum capacity of 4 x 50 mL tubes.

Automatically generated - may contain errors

Lab products found in correlation

Be0036, by BioXCell (2 mentions) Imipramine, by Merck Group (1 mentions) Be0055, by BioXCell (1 mentions) Be0085, by BioXCell (1 mentions) Be0061, by BioXCell (1 mentions) Be0131, by BioXCell (1 mentions) Be0090, by BioXCell (1 mentions) Bp0003 1, by BioXCell (1 mentions) Be0146, by BioXCell (1 mentions) Rmp1 14, by BioXCell (1 mentions)

2 protocols using be0290

NK Cell Depletion, IL-18 Therapy, and IFN-γ Blockade

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

For NK cell depletion, mice were injected IP with 100 μg anti-NK1.1 (PK136, BioXcell, BE0036) or isotype control (C1.18.4, BioXCell, BE0085). Depletion of NK1.1-positive cells was confirmed by flow cytometry. For IL-18 therapies, mice were injected IP with 0.2 μg recombinant mouse IL-18 (rmIL-18; MBL) at the time of infection, and daily until harvest as we previously described^{23 (link)}. For ASM depletion, mice were injected IP with 10mg/kg/mouse of imipramine (Sigma) or PBS control beginning at day −1 prior to infection, then daily. For in vivo IFN-γ blockade, mice were injected IP with 500 μg/mouse of anti-mouse IFN-γ (XMG1.2, BioXcell, BE0055) or isotype (Rat IgG1, BioXcell BE0290) control beginning at day −1 prior to infection, then every other day.

Nozaki K., Maltez V.I., Rayamajhi M., Tubbs A.L., Mitchell J.E., Lacey C.A., Harvest C.K., Li L., Nash W.T., Larson H.N., McGlaughon B.D., Moorman N.J., Brown M.G., Whitmire J.K, & Miao E.A. (2022). Caspase-7 activates ASM to repair gasdermin and perforin pores. Nature, 606(7916), 960-967.

+ Open protocol

+ Expand

In vivo immune checkpoint blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vivo experiments, mice were treated with anti-CTLA-4 (200 µg; Bio X Cell; BE0131) or anti-PD-1 antibody (200 μg; RMP1-14, Bio X Cell; BE0146) three times per week via intraperitoneal injection. Anti-NK1.1 (250 µg; Bio X Cell; BE0036), anti-CD8 (200 µg; Bio X Cell; BE0061), anti-CD4 (200 µg; Bio X Cell; BP00031) or the respective isotype control (Bio X Cell; BE0290 or BE0090) was given twice per week by intraperitoneal injection.

Leibold J., Tsanov K.M., Amor C., Ho Y.J., Sánchez-Rivera F.J., Feucht J., Baslan T., Chen H.A., Tian S., Simon J., Wuest A., Wilkinson J.E, & Lowe S.W. (2024). Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nature Cancer, 5(2), 315-329.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!